Aquestive Therapeutics, Inc. AQST Business Segments — Operating Income (Loss)
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Aquestive Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The official record: Aquestive Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aquestive Therapeutics, Inc.'s business segments — operating income (loss).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Aquestive Therapeutics, Inc.'s business segments — operating income (loss)?
- Aquestive Therapeutics, Inc. (AQST) reported business segments — operating income (loss) of -$4.2M in Q1 2026.
- How has Aquestive Therapeutics, Inc.'s business segments — operating income (loss) changed year-over-year?
- Aquestive Therapeutics, Inc.'s business segments — operating income (loss) increased by 78.3% year-over-year, from -$19.37M to -$4.2M.
- What is the long-term trend for Aquestive Therapeutics, Inc.'s business segments — operating income (loss)?
- Over 2 years (2023 to 2025), Aquestive Therapeutics, Inc.'s business segments — operating income (loss) has grown at a 116.9% compound annual growth rate (CAGR), from -$15.1M to -$71.05M.
- What does business segments — operating income (loss) mean?
- Measures the profit or loss generated by the segment from its core business activities, calculated as revenues minus total operating costs and expenses. This is the primary metric for assessing the operational performance and financial viability of the segment independent of financing or tax structures. A positive value indicates a self-sustaining business unit, while a negative value highlights the need for operational improvement or external funding.